28 adult patients with chronic HIV-1 infection were randomly assigned to receive raltegravir and maraviroc ... (vol 2, pg e72, 2015)

被引：2

|

作者：

Molina, J. M.

Clotet, B.

van Lunzen, J.

机构：

来源：

LANCET HIV | 2015年 / 2卷 / 04期

关键词：

D O I：

10.1016/S2352-3018(15)00043-0

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

收藏

页码：E126 / E126

页数：1

相关论文

共 11 条

[1] Complete response to treatment with doxycycline in patients with HIV-1 infection with lymphogranuloma venereum proctitis vol 28, pg 124, 2011
Heras, Eva
Llibre, Josep M.
Martro, Elisa
Casabona, Jordi
Martin-Iguacel, Raquel
Sirera, Guillem
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2012, 30 (06): : 357 - 357
[2] Hepatic Safety in Subjects With HIV-1 and Hepatitis C and/or B Virus: A Randomised, Double-Blind Study of Maraviroc vs Placebo in Combination With Antiretroviral Agents (vol 16, pg 72, 2015)
Rockstroh, Juergen K.
Soriano, Vicente
Plonski, Frank
Bansal, Meena
Faetkenheuer, Gerd
Small, Catherine B.
Asmuth, David M.
Pialoux, Gilles
Mukwaya, Geoffrey
Jagannatha, Shyla
Heera, Jayvant
Pineda, Juan A.
HIV CLINICAL TRIALS, 2015, 16 (06): : 236 - 238
[3] Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection (vol 10, e0118228, 2015)
Amin, Janaki
Boyd, Mark A.
Kumarasamy, Nagalingeswaran
Moore, Cecilia L.
Losso, Marcello H.
Nwizu, Chidi A.
Mohapi, Lerato
Kerr, Stephen J.
Sohn, Annette H.
Teppler, Hedy
Renjifo, Boris
Molina, Jean-Michel
Emery, Sean
Cooper, David A.
PLOS ONE, 2015, 10 (10):
[4] Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial (vol 374, pg 796, 2009)
Lennox, J. L.
Dejesus, E.
Lazzarin, A.
LANCET, 2009, 374 (9692): : 786 - 786
[5] Effect of baseline CD4 cell count at linkage to HIV care and at initiation of antiretroviral therapy on mortality in HIV-positive adult patients in Rwanda: a nationwide cohort study (vol 2, pg e368, 2015)
Nsanzimana, S.
Remera, E.
Kanters, S.
LANCET HIV, 2015, 2 (09): : E364 - E364
[6] Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial (vol 70, pg 515, 2015)
Walmsley, S.
Baumgarten, A.
Berenguer, J.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 71 (01) : E33 - E33
[7] STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial (vol 374, pg 796, 2009)
Lennox, J. L.
DeJesus, E.
Lazzarin, A.
LANCET, 2009, 374 (9707): : 2054 - 2054
[8] Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study (vol 381, pg 735, 2013)
Raffi, F.
Rachlis, A.
Stellbrink, H-J
LANCET, 2014, 384 (9946): : 856 - 856
[9] Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials (vol 369, pg 1169, 2007)
Clotet, B.
Bellos, N.
Molina, J. -M
LANCET, 2008, 371 (9607): : 116 - 116
[10] Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial (vol 13, pg 927, 2013)
Raffi, F.
Jaeger, H.
Quiros-Roldan, E.
LANCET INFECTIOUS DISEASES, 2014, 14 (08): : 675 - 675